CBI signs definitive share purchase agreement to obtain GL Biochem Commonwealth Biotechnologies.

Xu and four extra GL Group nominee directors. Related StoriesCombatting viral and bacterial lung infections with volatile anesthetics: an interview with Dr ChakravarthyUniversity of Leicester awarded BBSRC grant to explore three key areas that impact human healthAllergan signs licensing contract with Mimetogen to develop, commercialize tavilermide for treatment of dry eye diseaseIndustry Context Peptides play an important part in modulating many physiological procedures in the body and therefore have exceptional potential as therapeutic agents. Peptide drugs have a number of advantages over both small molecules and proteins, including lower immunogenicity and toxicity, excellent specificity, high potency and a minimal probability of drug-drug interaction complications. Several technical difficulties in the usage of peptides as medications have been overcome in recent years plus they now represent one of the key development areas in the drug discovery sector.Boehringer Ingelheim is a head in cardiometabolic disease study and development and provides ambitious strategic goals in diabetes and fat burning capacity. The new collaboration is supposed to broaden Boehringer Ingelheim’s pipeline in this region. Consuming disorders are among the main contributing elements to the advancement of overweight and weight problems which are main risk elements for type 2 diabetes, cardiovascular disease, high blood circulation pressure, and other health issues. Circuit’s optogenetics technology will be utilized to recognize targets in central anxious circuits relevant for weight problems, and peripheral and central circuits relevant for coordinating diet. These insights provides both companies with an improved knowledge of the mechanisms involved with obesity. It will enable the prioritization of novel targets with a prospect of therapeutic intervention more advanced than current standard of treatment in weight problems.